454 related articles for article (PubMed ID: 31162316)
1. Pregnancy and Family Planning in Multiple Sclerosis.
Langer-Gould AM
Continuum (Minneap Minn); 2019 Jun; 25(3):773-792. PubMed ID: 31162316
[TBL] [Abstract][Full Text] [Related]
2. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
Berenguer-Ruiz L; Gimenez-Martinez J; Palazón-Bru A; Sempere AP
J Neurol; 2019 Oct; 266(10):2512-2517. PubMed ID: 31256279
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic inertia in relapsing-remitting multiple sclerosis.
Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
[TBL] [Abstract][Full Text] [Related]
7. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
Varytė G; Zakarevičienė J; Ramašauskaitė D; Laužikienė D; Arlauskienė A
Medicina (Kaunas); 2020 Jan; 56(2):. PubMed ID: 31973138
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy and multiple sclerosis: an update.
Varytė G; Arlauskienė A; Ramašauskaitė D
Curr Opin Obstet Gynecol; 2021 Oct; 33(5):378-383. PubMed ID: 34310364
[TBL] [Abstract][Full Text] [Related]
10. Drugs for multiple sclerosis.
Med Lett Drugs Ther; 2021 Mar; 63(1620):42-48. PubMed ID: 33976089
[No Abstract] [Full Text] [Related]
11. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
12. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
MacDonald SC; McElrath TF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
[TBL] [Abstract][Full Text] [Related]
13. Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy.
Hellwig K; Tokic M; Thiel S; Esters N; Spicher C; Timmesfeld N; Ciplea AI; Gold R; Langer-Gould A
JAMA Netw Open; 2022 Jan; 5(1):e2144750. PubMed ID: 35072719
[TBL] [Abstract][Full Text] [Related]
14. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.
Maniscalco GT; Saccà F; Lanzillo R; Annovazzi P; Baroncini D; Binello E; Repice A; Perini P; Clerico M; Mataluni G; Bonavita S; La Gioia S; Gutierrez LP; Laroni A; Frau J; Cocco E; Torri Clerici V; Zarbo IR; Sartori A; Signoriello E; Rasia S; Cordioli C; Stromillo ML; Cerqua R; Pontecorvo S; Di Sapio A; Grasso R; Barone S; Lavorgna L; Barrilà C; Landi D; Russo CV; Frigeni B; Ippolito D; Turano G; Carmisciano L; Sormani MP; Signori A
Mult Scler Relat Disord; 2020 Jul; 42():102059. PubMed ID: 32208344
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H
Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738
[TBL] [Abstract][Full Text] [Related]
16. Early Relapsing Multiple Sclerosis.
Jones DE
Continuum (Minneap Minn); 2016 Jun; 22(3):744-60. PubMed ID: 27261680
[TBL] [Abstract][Full Text] [Related]
17. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.
Amato MP; Portaccio E
CNS Drugs; 2015 Mar; 29(3):207-20. PubMed ID: 25773609
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
19. Update on disease-modifying treatments for multiple sclerosis.
Carrithers MD
Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
[TBL] [Abstract][Full Text] [Related]
20. [Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
Akatani R; Chihara N; Katanazaka K; Ueda T; Sekiguchi K; Matsumoto R
Rinsho Shinkeigaku; 2019 Aug; 59(8):536-540. PubMed ID: 31341130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
